In this setting, MET amplification has been reported in 5–20% of lung cancers with resistance to EGFR inhibitors (10, 22) Sequencing of therapy for patients with EGFR mutant NSCLC is in evolution, and based on Phase III results demonstrated improved PFS with osimertinib in the front-line setting for these patients (4), new mechanisms of acquired resistance will emerge. Here, MET is linked to non-small cell lung carcinoma.